Hemogenyx Pharmaceuticals Plc (HOPHF) Stock Price & Analysis
Hemogenyx Pharmaceuticals Plc (HOPHF) — price $2.33 (0.00%), as of the Oct 5, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Hemogenyx Pharmaceuticals Plc · HOPHF
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology company focused on developing therapies for blood diseases, particularly in the bone marrow transplant space. Their pipeline includes CDX bi-specific antibodies, HEMO-CAR-T therapy, and Human Postnatal Hematopoietic Endothelial Cells.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $2.33 |
| Change on the day | 0.00% |
| Shares traded on the day | 25.0K |
Price & events
Other perspectives
Council score for Hemogenyx Pharmaceuticals (HOPHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the HOPHF film — every key number, told as a short cinematic story
~2 min · open the film
What is Hemogenyx Pharmaceuticals (HOPHF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Hemogenyx Pharmaceuticals Plc (HOPHF) is the company analyzed here. It employs 16 people. In Q4 FY2025 it reported revenue of $0 and net income of -$6M.
What do the latest results show for Hemogenyx Pharmaceuticals (HOPHF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $0.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $0 | -$6M | -$1.04 (diluted) |
| Q2 FY2025 | $0 | -$7M | -$1.87 (diluted) |
| Q4 FY2024 | $0 | -$7M | -$2.12 (diluted) |
| Jun 2024 | $0 | -$3,716.536 | -$1.21 (diluted) |
What are the financial strengths and risks for Hemogenyx Pharmaceuticals (HOPHF)?
Short answer
The distress and quality screens read Altman Z -15.36 · Piotroski F 1. Trailing ratios: current ratio 1.38 · earnings yield -33.4% · free-cash-flow yield -10.5%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -15.36 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What has been published about Hemogenyx Pharmaceuticals (HOPHF)?
Hemogenyx Pharmaceuticals Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the HOPHF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is HOPHF a good stock to buy?
Stock Expert AI does not rate HOPHF buy, sell or hold. Hemogenyx Pharmaceuticals Plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HOPHF stock price today?
The last price recorded on this page for Hemogenyx Pharmaceuticals Plc (HOPHF) is $2.33, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for HOPHF?
The main risks for Hemogenyx Pharmaceuticals Plc include the inherent uncertainties associated with drug development, particularly clinical trial failures and regulatory hurdles.
What are the key factors to evaluate for HOPHF?
Evaluate HOPHF on fundamentals, analyst consensus, and risk factors. Focus on Bone Marrow/Hematopoietic Stem Cell (BM/HSC) transplant market addresses a critical area of unmet medical need. Not financial advice.
How frequently does HOPHF data refresh on this page?
HOPHF's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HOPHF's recent stock price performance?
Hemogenyx Pharmaceuticals Plc (HOPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative therapeutic approaches for blood diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HOPHF overvalued or undervalued right now?
Hemogenyx Pharmaceuticals Plc (HOPHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HOPHF before investing?
Before investing in Hemogenyx Pharmaceuticals Plc (HOPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (10 figures)
The 10 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $2.33 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T17:14:42.644Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 25.0K | FMP | Financial Modeling Prep (FMP) · quote | |
id.employees | Employees | 16 | FMP | Financial Modeling Prep (FMP) · company profile — Captured 2026-10-04 | |
fin.q_revenue | Revenue, Q4 FY2025 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2025 | -$6M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z -15.36 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 1.38 · earnings yield -33.4% · free-cash-flow yield -10.5% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.